Skip to main content
INmune Bio, Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
4.870
+0.110 (2.31%)
Nov 22, 2024, 4:00 PM EST - Market closed

INmune Bio Revenue

INmune Bio had revenue of $42.00K in the twelve months ending September 30, 2024, down -81.25% year-over-year. In the year 2023, INmune Bio had annual revenue of $155.00K, down -58.56%.

Revenue (ttm)
$42.00K
Revenue Growth
-81.25%
P/S Ratio
n/a
Revenue / Employee
$2,471
Employees
17
Market Cap
107.98M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023155.00K-219.00K-58.56%
Dec 31, 2022374.00K193.00K106.63%
Dec 31, 2021181.00K170.00K1,545.45%
Dec 31, 202011.00K--
Dec 31, 2019---
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
MultiPlan 942.61M
Karyopharm Therapeutics 148.44M
Journey Medical 57.77M
Coya Therapeutics 9.55M
Avalo Therapeutics 820.00K
Inovio Pharmaceuticals 203.41K
Revenue Rankings

INMB News

More News